skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 21 - 40 of 460  for All Library Resources

previous page 1 Results 2 3 4 5 next page
Refined by: Journal Title: Bmc Cancer remove subject: Tumors remove
Result Number Material Type Add to My Shelf Action Record Details and Options
21
INHBA is a prognostic predictor for patients with colon adenocarcinoma
Material Type:
Article
Add to My Research

INHBA is a prognostic predictor for patients with colon adenocarcinoma

BMC cancer, 2020-04, Vol.20 (1), p.305-305, Article 305 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-020-06743-2 ;PMID: 32293338

Full text available

22
Advances in personalized radiotherapy
Material Type:
Article
Add to My Research

Advances in personalized radiotherapy

BMC cancer, 2024-05, Vol.24 (1), p.556-556 [Peer Reviewed Journal]

2024. The Author(s). ;COPYRIGHT 2024 BioMed Central Ltd. ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-024-12317-3 ;PMID: 38702617

Full text available

23
A gene expression-based study on immune cell subtypes and glioma prognosis
Material Type:
Article
Add to My Research

A gene expression-based study on immune cell subtypes and glioma prognosis

BMC cancer, 2019-11, Vol.19 (1), p.1116-1116, Article 1116 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;The Author(s). 2019 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-019-6324-7 ;PMID: 31729963

Full text available

24
Exosome-transmitted circ_002136 promotes hepatocellular carcinoma progression by miR-19a-3p/RAB1A pathway
Material Type:
Article
Add to My Research

Exosome-transmitted circ_002136 promotes hepatocellular carcinoma progression by miR-19a-3p/RAB1A pathway

BMC cancer, 2022-12, Vol.22 (1), p.1284-1284 [Peer Reviewed Journal]

2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-022-10367-z ;PMID: 36476239

Full text available

25
Identification of a pyroptosis-related prognostic signature in breast cancer
Material Type:
Article
Add to My Research

Identification of a pyroptosis-related prognostic signature in breast cancer

BMC cancer, 2022-04, Vol.22 (1), p.429-429, Article 429 [Peer Reviewed Journal]

2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-022-09526-z ;PMID: 35443644

Full text available

26
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Material Type:
Article
Add to My Research

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

BMC cancer, 2020-03, Vol.20 (1), p.230-230, Article 230 [Peer Reviewed Journal]

COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-020-06727-2 ;PMID: 32188412

Full text available

27
Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image
Material Type:
Article
Add to My Research

Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image

BMC cancer, 2023-10, Vol.23 (1), p.1-1012, Article 1012 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11544-4 ;PMID: 37864148

Full text available

28
Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis
Material Type:
Article
Add to My Research

Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis

BMC cancer, 2023-10, Vol.23 (1), p.1-1004, Article 1004 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11452-7

Full text available

29
Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
Material Type:
Article
Add to My Research

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study

BMC cancer, 2023-09, Vol.23 (1), p.1-873, Article 873 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11389-x ;PMID: 37718456

Full text available

30
Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy
Material Type:
Article
Add to My Research

Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy

BMC cancer, 2023-11, Vol.23 (1), p.1-1150, Article 1150 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11629-0

Full text available

31
Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer
Material Type:
Article
Add to My Research

Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer

BMC cancer, 2021-08, Vol.21 (1), p.1-905, Article 905 [Peer Reviewed Journal]

COPYRIGHT 2021 BioMed Central Ltd. ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-021-08629-3 ;PMID: 34364366

Full text available

32
Incidence and risk factors of acute kidney injury in patients with malignant tumors: a systematic review and meta-analysis
Material Type:
Article
Add to My Research

Incidence and risk factors of acute kidney injury in patients with malignant tumors: a systematic review and meta-analysis

BMC cancer, 2023-11, Vol.23 (1), p.1-1123, Article 1123 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11561-3

Full text available

33
Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma
Material Type:
Article
Add to My Research

Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma

BMC cancer, 2021-07, Vol.21 (1), p.1-866, Article 866 [Peer Reviewed Journal]

COPYRIGHT 2021 BioMed Central Ltd. ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-021-08596-9 ;PMID: 34320931

Full text available

34
Clinical retrospective analysis with a predictive model for diffused-tenosynovial giant cell tumors of the temporomandibular joint
Material Type:
Article
Add to My Research

Clinical retrospective analysis with a predictive model for diffused-tenosynovial giant cell tumors of the temporomandibular joint

BMC cancer, 2023-11, Vol.23 (1), p.1-1062, Article 1062 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11587-7

Full text available

35
Prognostic significance of HLA-G in patients with colorectal cancer: a meta-analysis and bioinformatics analysis
Material Type:
Article
Add to My Research

Prognostic significance of HLA-G in patients with colorectal cancer: a meta-analysis and bioinformatics analysis

BMC cancer, 2023-10, Vol.23 (1), p.1-1024, Article 1024 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11522-w

Full text available

36
Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation
Material Type:
Article
Add to My Research

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

BMC cancer, 2023-10, Vol.23 (1), p.1-1017, Article 1017 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11485-y ;PMID: 37867191

Full text available

37
The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
Material Type:
Article
Add to My Research

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

BMC cancer, 2023-10, Vol.23 (1), p.1-1018, Article 1018 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11523-9

Full text available

38
Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution
Material Type:
Article
Add to My Research

Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution

BMC cancer, 2023-10, Vol.23 (1), p.1-984, Article 984 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11505-x

Full text available

39
Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma
Material Type:
Article
Add to My Research

Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma

BMC cancer, 2022-04, Vol.22 (1), p.431-431, Article 431 [Peer Reviewed Journal]

2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-022-09530-3 ;PMID: 35443674

Full text available

40
MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib
Material Type:
Article
Add to My Research

MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib

BMC cancer, 2023-10, Vol.23 (1), p.1-967, Article 967 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-023-11320-4

Full text available

Results 21 - 40 of 460  for All Library Resources

previous page 1 Results 2 3 4 5 next page

Searching Remote Databases, Please Wait